Gilead Sciences, Inc. (GILD) Receives $87.95 Consensus Price Target from Analysts

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-five analysts that are covering the company, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $87.59.

Several brokerages recently commented on GILD. Morgan Stanley boosted their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Thursday, July 26th. Piper Jaffray Companies set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th.

Shares of NASDAQ:GILD traded down $0.87 during trading on Friday, hitting $69.44. 6,047,464 shares of the stock traded hands, compared to its average volume of 7,387,994. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.47 and a quick ratio of 3.39. The firm has a market cap of $90.02 billion, a price-to-earnings ratio of 8.11, a price-to-earnings-growth ratio of -2.69 and a beta of 1.01. Gilead Sciences has a 52-week low of $64.27 and a 52-week high of $89.54.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the previous year, the firm earned $2.27 EPS. On average, sell-side analysts anticipate that Gilead Sciences will post 6.44 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s payout ratio is 26.64%.

In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Northwest Bancshares Inc. boosted its position in shares of Gilead Sciences by 8.9% during the 3rd quarter. Northwest Bancshares Inc. now owns 28,816 shares of the biopharmaceutical company’s stock valued at $2,224,000 after acquiring an additional 2,344 shares during the last quarter. DnB Asset Management AS boosted its position in shares of Gilead Sciences by 4.4% during the 2nd quarter. DnB Asset Management AS now owns 156,552 shares of the biopharmaceutical company’s stock valued at $11,090,000 after acquiring an additional 6,600 shares during the last quarter. Swedbank boosted its position in shares of Gilead Sciences by 103.7% during the 3rd quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock valued at $301,596,000 after acquiring an additional 1,988,987 shares during the last quarter. Fairpointe Capital LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $708,000. Finally, IFM Investors Pty Ltd boosted its position in shares of Gilead Sciences by 15.8% during the 3rd quarter. IFM Investors Pty Ltd now owns 68,466 shares of the biopharmaceutical company’s stock valued at $5,286,000 after acquiring an additional 9,342 shares during the last quarter. 78.23% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply